Welcure Drugs & Pharmaceuticals Ltd. to Consider 25% Equity Stake Acquisition by Telexcell Trade PTE LTD at Premium Price
Welcure Drugs & Pharmaceuticals Ltd. has informed BSE that the Board of Directors of the company will consider and approve a meeting on 27th September 2025. The meeting was initially scheduled for 25th September 2025 to discuss a Letter of Intent (LOI) received from Telexcell Trade PTE LTD, Singapore, proposing an acquisition of up to 25% equity stake in Welcure Drugs & Pharmaceuticals Ltd. at an indicative price of 220 per share. The company will initiate comprehensive due diligence, including legal, financial, and regulatory aspects, and authorize representatives to negotiate and finalize the terms of definitive agreements. Welcure will also explore future strategic growth opportunities in global pharmaceutical and chemical exports, leveraging Telexcell's global trade network. The meeting was rescheduled due to the non-availability of directors.
Key Highlights
- Welcure Drugs & Pharmaceuticals Ltd. received a Letter of Intent (LOI) from Telexcell Trade PTE LTD, Singapore, for a proposed acquisition of up to 25% equity stake.
- The proposed acquisition price is 220 per share, a substantial premium over the prevailing market price.
- The company will initiate comprehensive due diligence and negotiate definitive agreements with Telexcell.
- Welcure will explore future strategic growth opportunities in global pharmaceutical and chemical exports.
- The Board Meeting was rescheduled due to non-availability of directors.